SCV
ACRV icon

Sands Capital Ventures’s Acrivon Therapeutics ACRV Stock Holding History

Sands Capital Ventures’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07M Buy
2,289,271
+166,666
+8% +$283K 0.66% 23
2026
Q1 		$2.95M Hold
2,122,605
– – 0.7% 19
2025
Q4 		$5.12M Hold
2,122,605
– – 0.99% 16
2025
Q3 		$3.84M Hold
2,122,605
– – 0.84% 17
2025
Q2 		$2.53M Hold
2,122,605
– – 0.5% 17
2025
Q1 		$4.31M Hold
2,122,605
– – 1.05% 13
2024
Q4 		$12.8M Hold
2,122,605
– – 2.78% 8
2024
Q3 		$14.9M Hold
2,122,605
– – 4.18% 5
2024
Q2 		$12.3M Buy
2,122,605
+470,000
+28% +$3.79M 4.12% 6
2024
Q1 		$11.8M Hold
1,652,605
– – 2.85% 8
2023
Q4 		$8.13M Hold
1,652,605
– – 2.26% 9
2023
Q3 		$15.8M Hold
1,652,605
– – 4.67% 9
2023
Q2 		$21.4M Hold
1,652,605
– – 6.34% 7
2023
Q1 		$21M Hold
1,652,605
– – 5.18% 8
2022
Q4 		$19M Buy
+1,652,605
New +$21M 5.21% 7

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Sands Capital Ventures's ACRV Position: Q2 2026 in Review

Sands Capital Ventures increased its Acrivon Therapeutics (ACRV) stake by 7.9% in Q2 2026, buying an estimated $283K and bringing the position to 2,289,271 shares worth $4.07M. The position accounts for 0.66% of the portfolio, ranked #23.

Sands Capital Ventures first reported a position in ACRV in Q4 2022 and has held it in 15 quarters since. The position peaked at $21.4M in Q2 2023. 43 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Sands Capital Ventures held 2,289,271 shares of Acrivon Therapeutics worth $4.07M as of Q2 2026.
  • Sands Capital Ventures bought 166,666 Acrivon Therapeutics shares in Q2 2026, an estimated $283K.
  • Acrivon Therapeutics made up 0.66% of Sands Capital Ventures's portfolio in Q2 2026, its #23 holding.
  • Sands Capital Ventures first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Sands Capital Ventures's Acrivon Therapeutics position peaked at $21.4M in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.